112 related articles for article (PubMed ID: 23580960)
21. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
[TBL] [Abstract][Full Text] [Related]
22. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
[TBL] [Abstract][Full Text] [Related]
23. NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH.
Szijan I; Rochefort D; Bruder C; Surace E; Machiavelli G; Dalamon V; Cotignola J; Ferreiro V; Campero A; Basso A; Dumanski JP; Rouleau GA
Neuromolecular Med; 2003; 3(1):41-52. PubMed ID: 12665675
[TBL] [Abstract][Full Text] [Related]
24. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
25. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
[TBL] [Abstract][Full Text] [Related]
27. Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.
Buccoliero AM; Gheri CF; Castiglione F; Ammannati F; Gallina P; Taddei A; Garbini F; Rossi Degl'Innocenti D; Arganini L; Di Lorenzo N; Mennonna P; Taddei GL
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):353-7. PubMed ID: 17721284
[TBL] [Abstract][Full Text] [Related]
28. Whole-genome sequencing identifies new genetic alterations in meningiomas.
Tang M; Wei H; Han L; Deng J; Wang Y; Yang M; Tang Y; Guo G; Zhou L; Tong A
Oncotarget; 2017 Mar; 8(10):17070-17080. PubMed ID: 28177878
[TBL] [Abstract][Full Text] [Related]
29. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
30. Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
van Tilborg AA; Morolli B; Giphart-Gassler M; de Vries A; van Geenen DA; Lurkin I; Kros JM; Zwarthoff EC
J Pathol; 2006 Mar; 208(4):564-73. PubMed ID: 16353169
[TBL] [Abstract][Full Text] [Related]
31. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
[TBL] [Abstract][Full Text] [Related]
32. Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms.
Heinrich B; Hartmann C; Stemmer-Rachamimov AO; Louis DN; MacCollin M
Int J Cancer; 2003 Feb; 103(4):483-8. PubMed ID: 12478663
[TBL] [Abstract][Full Text] [Related]
33. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
34. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
[TBL] [Abstract][Full Text] [Related]
35. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
36. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
[TBL] [Abstract][Full Text] [Related]
38. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
Burns SS; Chang LS
Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
[TBL] [Abstract][Full Text] [Related]
39. Interstitial loss and gain of sequences on chromosome 22 in meningiomas with normal karyotype.
Prowald A; Wemmert S; Biehl C; Storck S; Martin T; Henn W; Ketter R; Meese E; Zang KD; Steudel WI; Urbschat S
Int J Oncol; 2005 Feb; 26(2):385-93. PubMed ID: 15645123
[TBL] [Abstract][Full Text] [Related]
40. [NF2].
Takeshima H; Ushio Y
No To Shinkei; 1998 Jun; 50(6):529-37. PubMed ID: 9656248
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
